[HTML][HTML] The role of the tumour microenvironment in immunotherapy
Recent success in immunomodulating strategies in lung cancer and melanoma has
prompted much enthusiasm in their potential to treat other advanced solid malignancies …
prompted much enthusiasm in their potential to treat other advanced solid malignancies …
The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
W Ke, L Zhang, Y Dai - Thoracic cancer, 2020 - Wiley Online Library
IL‐6 is a cytokine that plays an important role in response to injury or infection and is a
promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell …
promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell …
[HTML][HTML] m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD
F Xu, X Huang, Y Li, Y Chen, L Lin - Molecular Therapy-Nucleic Acids, 2021 - cell.com
Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer worldwide.
However, the survival rate of LUAD patients remains low. N6-methyladenosine (m 6 A) and …
However, the survival rate of LUAD patients remains low. N6-methyladenosine (m 6 A) and …
Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer
In non–small cell lung cancer (NSCLC), response to immune checkpoint blockade (ICB) is
associated with programmed cell death ligand 1 expression that is induced by interferon-γ …
associated with programmed cell death ligand 1 expression that is induced by interferon-γ …
[HTML][HTML] LncRNA NEAT1 interacted with DNMT1 to regulate malignant phenotype of cancer cell and cytotoxic T cell infiltration via epigenetic inhibition of p53, cGAS …
F Ma, YY Lei, MG Ding, LH Luo, YC Xie, XL Liu - Frontiers in genetics, 2020 - frontiersin.org
Purpose Lung cancer is the main cause of cancer-related mortality worldwide. We report
here the biological role of nuclear paraspeckle assembly transcript 1 (NEAT1) in the …
here the biological role of nuclear paraspeckle assembly transcript 1 (NEAT1) in the …
Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1α activation
M Wang, J Yan, X Cao, P Hua, Z Li - Biochemical Pharmacology, 2020 - Elsevier
Hydrogen sulfide (H 2 S) has been frequently implicated in tumor progression. However, the
exact regulation mechanism of H 2 S in human non-small cell lung cancer (NSCLC) has not …
exact regulation mechanism of H 2 S in human non-small cell lung cancer (NSCLC) has not …
Previous immune checkpoint inhibitor treatment to increase the efficacy of docetaxel and ramucirumab combination chemotherapy
D Harada, K Takata, S Mori, T Kozuki… - Anticancer …, 2019 - ar.iiarjournals.org
Background/Aim: For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and
ramucirumab (DOC+ RAM) combination therapy may be more effective compared to patients …
ramucirumab (DOC+ RAM) combination therapy may be more effective compared to patients …
EZH2 is a potential prognostic predictor of glioma
Y Chen, S Hou, R Jiang, J Sun… - Journal of cellular and …, 2021 - Wiley Online Library
The enhancer of zeste homologue 2 (EZH2) is a histone H3 lysine 27 methyltransferase that
promotes tumorigenesis in a variety of human malignancies by altering the expression of …
promotes tumorigenesis in a variety of human malignancies by altering the expression of …
[HTML][HTML] Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
W Shalata, J Zolnoorian, G Migliozzi, AA Jama… - International Journal of …, 2023 - mdpi.com
Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be
vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the …
vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the …
[HTML][HTML] lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α
G Jiang, H Yu, Z Li, F Zhang - … journal of oncology, 2021 - spandidos-publications.com
The present study aimed to explore the role of the long noncoding RNA cytoskeleton
regulator (CYTOR) in non‑small cell lung cancer (NSCLC) radiosensitivity by manipulating …
regulator (CYTOR) in non‑small cell lung cancer (NSCLC) radiosensitivity by manipulating …